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Abstract. Ivermectin is an antiparasitic drug with a broad spectrum of activity, high efﬁcacy as well as a
wide margin of safety. Since 1987, this compound has a widespread use in veterinary medicine and it use
has been extended in humans. Here we present a brief review of the information availabile regarding the
pharmacokinetics and interactions of ivermectin in humans. Awareness of these characteristics could
improve the clinical efﬁcacy of Ivermectin. All Authors declare that they do not have any Conﬂict of
interest and that the work is original. All Authors agree that the contents of the manuscript are
conﬁdential and will not be copyrighted, submitted, or published elsewhere (including the Internet), in
any language, while acceptance by the Journal is under consideration.
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INTRODUCTION
Ivermectin is a semisynthetic derivative of avermectin B1
and consists of an 80:20 mixture of the equipotent homolo-
gous 22,23 dehydro B1a and B1b. This antiparasitic agent,
developed by Merck & Co., is frequently used in veterinary
medicine, due to its broad spectrum of activity, high efﬁcacy
and wide margin of safety (1,2).
The ﬁrst formulation destined to humans was launched
in 1987, when Merck Laboratories had enough data to
register ivermectin for use against onchocerciasis. The
company announced that the drug would be provided at no
cost to treat onchocerciasis, anywhere in the world, for as
long as it was needed (3).
To control onchocerciasis, the Onchocerciasis Control
Programme in West Africa was launched in 1974. The main
goal of this program is to interrupt the parasite transmission
cycle. Since 1987, the use of ivermectin in combination with
aerial larviciding has had a remarkable impact on the
transmission of the disease and greatly reduced the effect on
humans. This led to the development, in 1992, of the
Onchocerciasis Elimination Programme in the Americas,
launched in 6 countries and, in 1995, of the African
Programme for Onchocerciasis Control, both based mainly
on distribution and treatment with ivermectin (4). In 1998,
the Global Programme to Eliminate Lymphatic Filariasis,
based on the regular mass administration of albendazole with
either ivermectin or diethylcarbamazine, was initiated, con-
ﬁrming the safety and efﬁcacy of the drug combinations (5).
Presently, ivermectin is approved for use in humans in
several countries (Australia, France, Japan, The Netherlands,
USA, etc.), to treat onchocerciasis, lymphatic ﬁlariasis,
strongiloidiasis and/or scabies.
Ivermectin is exceptionally potent, with effective dosages
levels that are unusually low. In the treatment of onchocer-
ciasis, the optimal dose of ivermectin is 150 μg/kg, but the
frequency of administration is still controversial, ranging from
150 μg/kg once to three times yearly. The optimal duration of
treatment has not been established (6). It is effective in most
patients with scabies after a single oral dose of 200 μg/kg, but
often the regimen involves two or three repeated doses,
separated by interval of 1 or 2 weeks (7).
Due to the extended use of this compound in humans,
the knowledge of ivermectin pharmacokinetic behavior
becomes essential. Nevertheless, little is known about the
kinetics and interactions of ivermectin in humans compared
to animals (even if the majority of fundamental work is
veterinary, there is little evidence that such knowledge has
helped to inform clinicians).
Thus, in this paper, we review the literature concerning
the absorption, distribution, metabolism and excretion of
ivermectin in man, as well as the interactions of the
compound.
PHARMACOKINETICS
The oral route is the only approved for ivermectin
administration in humans. The one-compartmental model
(8, 9), as well as the two-compartmental model (10) have
been used to describe ivermectin kinetic behavior after its
oral administration. In the rest of the studies cited here,
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Absorption
In healthy subjects that received 12 mg of ivermectin as
oral solution, tablets or capsules, it was shown that the
solution had approximately twice the systemic availability as
either of the solid forms (tablets and capsules showed similar
systemic availability; Table 1). The oral solution was given as
an ethanolic solution. This may affect bioavailability and
could explain why the solution resulted in a twice as high
availability as tablets and capsules. Nevertheless, the rate of
absorption was similar in the three cases (11).
In healthy and onchocerciasis volunteers treated with
150 μg/kg, no signiﬁcant differences were found in the
pharmacokinetic parameters calculated. After an initial de-
crease, both groups showed a tendency for a second rise in
plasma levels (mostly occurring between 6 and 12 h after the
dose) suggesting an enterohepatic recycling of the drug (12).
It was also investigated whether diminished ivermectin
absorption could explain the fact that some severely infected
onchocerciasis patients experience relatively few adverse
effects following ivermectin treatment, although the occur-
rence and extent of adverse reactions have been related to
infection intensity (17). According to this study, there was no
observable relation between the plasma concentration after a
single oral dose (150 μg/kg) and the occurrence of adverse
reactions. Neither parasite load nor ivermectin concentrations
had an inﬂuence on the occurrence of adverse reactions in the
entire group of patients.
The ability to achieve adequate levels of ivermectin after
oral administration in patients with disseminated strongyloidi-
asis may be impaired, highlighting the need for alternative
routes of administration of ivermectin in these patients. Thus,
ivermectin levels, in a patient with disseminated strongyloidi-
asis, were below the average of those reported by other
authors following oral administration (1.1 ng·ml
−1 after
ingesting a total dosage of 1,000 μg/kg over 3 consecutive
days). This was followed by the administration of three
subcutaneous doses (200 μg/kg), injected every 2 days,
increasing ivermectin levels to 7.9 ng·ml
−1 at 1 week after the
last dose, with evidence of additional metabolite accumulation
and also a sustained antiparasitic effect. Thus, in these patients,
who are unable to absorb oral medication, parenteral
ivermectin (not licensed for use in humans) is a better
option (18). In another report, a man with disseminated
strongyloidiasis, severe hypoalbuminemia and paralytic ileus,
received ivermectin by the oral route. Three hours after the
third daily dose, the serum ivermectin concentration was only
0.8 ng·ml
−1, but it increased to 5.8 ng·ml
−1 16 hours after the
ﬁrst subcutaneous dose. Over the next 15 days, subcutaneous
ivermectin (200 μg/kg, once a day) produced serum ivermectin
levels between 11.4 and 17.2 ng·ml
−1 with no signiﬁcant
accumulation (19).
Distribution
Due to the high lipid solubility of ivermectin, this
compound is widely distributed within the body.
In healthy men, the volume of distribution in the central
compartment, Vc, was 3.1 and 3.5 l·kg
−1, after ingesting 6 and
12 mg of ivermectin, respectively (8). In onchocerciasis
patients, with 6 mg (tablet), the volume of distribution of
the area (Vλ) was 9.9 l·kg
−1 and the mean residence time
(MRT) was 3.7 days (16).
The tissue distribution of ivermectin was similar in
healthy and onchocerciasis volunteers treated orally. So,
Table 1. Pharmacokinetic Parameters Obtained after Ivermectin Oral Administration
Reference Dose
Absorption Elimination
Cmax (ng·ml
−1) tmax (h) t1/2(abs) (h) t1/2 (h) Cl (1 kg
−1·day
−1)
Healthy subjects
9
a 12 mg (tablet) –– – 12 –
8
a 6 mg (tablet) 23.1 4.3 0.5 12.6 4.28
8
a 12 mg (tablet) 30.4 10.3 2.5 13.4 4.03
9
a 6 mg (tablet) 20.2 4.7 1.4 11.1 7.57
9
a 12 mg (tablet) 23.5 5.3 1.4 21.1 6.53
9
a 18 mg (tablet) 31.2 5.1 1.7 16.7 10.6
11 12 mg (solution) 81 3.6 –– –
11 12 mg (tablet) 50 3.4 –– –
11 12 mg (capsule) 46 3.6 –– –
12 150 μg/kg 54.4 4.9 – 36.6 –
13 150 μg/kg 37.9 –– – –
14 150 μg/kg 33.8 –– 4.70 (♂) 8.40 (♀)
Onchocerciasis patients
12 150 μg/kg 52.2 5.2 – 35.0 –
15 150 μg/kg 39 5.6 – 16 –
16 6 mg (tablet) 38.2 4.7 – 54.5 3.1
17 150 μg/kg 19.9 –
– Unknown data; Cmax maximum plasma concentration; tmax time to reach Cmax; t1/2abs absorption half-life; t1/2 elimination half-life; Cl total
body clearance
aOne-compartment model
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the distribution of this drug. The compound was present in
fat, skin, subcutaneous fascia and nodules and in worm
fragments. Fat showed the highest and most persistent levels,
whilst values for skin, nodular tissues, and worms were
comparable, being the lowest concentrations found in the
subcutaneous fascia (12). In patients with Onchocerca volvu-
lus infection treated orally with ivermectin (150 μg/kg),
Elkassaby (15) also detected the drug in the nodular tissue
of the parasite and in worm fragments. After subcutaneous
administration (500 μg/kg) to cattle with nodules of Oncho-
cerca ochengi (a cattle parasite that can be used as a model of
O. volvulus), high concentrations were detected in the
capsule wall and inside the nodule (55 and 45 ng·g
−1 on
day 2; 60 and 30 ng·g
−1 on day 7). So, the poor penetration of
ivermectin into the nodules could not explain the lack of
efﬁcacy against adult ﬁlariae (20).
In the skin, the peak concentration of the drug in
squames, sebum and sweat on the forehead and the antithenar
was 8 h after a 12 mg oral dose and decline quickly beyond
24 h (21).
Ivermectin binds strongly to plasma proteins in healthy
subjects (93.2%) (22). It was also high in onchocerciasis
patients (93.1%), with a speciﬁc binding for serum albumin.
There were two binding sites, with an association constant of
2×10
8 mol
−1 at the primary site. Such avid binding assumes
great importance as the drug is administered in world areas
where malnutrition and hypoalbuminemia are common, so in
these patients a decrease in plasma proteins and, consequently,
a higher free fraction of ivermectin could be expected.
Nevertheless, acetylsalicylic acid does not interfere with
ivermectin binding (16).
Ivermectin was not detected in the cerebrospinal ﬂuid of
a man with disseminated strongyloidiasis, severe hypoalbu-
minemia and paralytic ileus, after ﬁve subcutaneous doses of
ivermectin, when the serum level was 12.1 ng·ml
−1 (18).
Elimination
Studies regarding the metabolism of ivermectin in
humans are scarce. This drug is extensively metabolized by
human liver microsomes by cytochrome P450. The predom-
inant isoform responsible for the biotransformation of this
compound in the liver of humans is cytochrome P-4503A4,
converting the drug to at least 10 metabolites, most of them
hydroxylated and demethylated derivatives (23). In plasma,
radioactive metabolites were reported after the oral admin-
istration of ivermectin to healthy volunteers (10).
Data concerning excretion can be observed on Table 1.
No differences in the elimination half-life were detected
among healthy and onchocerciasis subjects (12). It was also
suggested that the kinetics of ivermectin (its elimination half-
life is around a day) were somewhat disconnected from its
pharmacodynamics (antiparasitic events persisting for several
months after a single dose of the drug) (11).
A signiﬁcant effect of gender was found in ivermectin
pharmacokinetics in healthy volunteers orally treated with
150 μg/kg, with a lower total body Cl/F in males compared to
females (see Table 1)( 14).
In connection with the excretion pathways, ivermectin
and its metabolites were excreted mainly in faeces and only
1% in urine. Positive identiﬁcation was obtained for the
presence of 3”-O-desmethyl-H2B1a, and 22,23-dihydroaver-
mectin B1a monosacharide in urine and faeces, respectively
10.
Other authors who tried to determine ivermectin in urine (8,
9, 16) did not ﬁnd the parent drug nor its metabolites.
Finally, in the milk of healthy women administered
150 μg/kg, the maximum concentration (14.1 ng·ml
−1) was
reached in 6.5 h (13). On the basis of this information, a
breast-fed child would receive an average dose of only
2.75 μg/kg via milk. Thus, these authors did not recommend
excluding breastfeeding mothers from mass ivermectin
therapies, as they only represent 5–10% of the population in
the areas hyperendemic with onchocerciasis.
INTERACTIONS
Several authors evaluated the effect of ivermectin
coadministration with different drugs employed to control
helminthes. To interrupt the transmission of onchocerciasis in
humans, the combination of ivermectin and doxycycline is
highly effective as, in infested patients, the ingestion of the
anthelmintic (200 μg/kg, single dose) and the antibacterial
(100 mg/kg, daily for 6 weeks), kept the microﬁladermia
levels low more time than did ivermectin alone. Doxycycline
enhanced ivermectin-induced suppression of microﬁladermia,
as it sterilize adult female worms for a few months by
depletion of symbiotic endobacteria of ﬁlariae, Wolbachia
spp. (24) (essential for their survival and reproduction).
Other studies showed that, to control onchocerciasis, the
combination of ivermectin with other drugs offers no
advantage over ivermectin alone. Thus, in infected patients,
the ingestion of ivermectin had no effect on the kinetics of an
oral dose of albendazole and there was no additive effect of
both drugs against the parasite compared to ivermectin given
alone (25, 26, 27). Albendazole (400 mg) did not modify the
kinetic behavior of a single oral ivermectin dose (12 mg) (27).
Also in onchocerciasis patients, the antiparasitary efﬁcacy
was similar when administering a single ivermectin dose
(150 μg/kg, on day 1) followed by amorcazine (3 mg/kg twice
daily, on days 8, 9 and 10) than when administering
ivermectin alone (28). Similarly, the combination of ivermec-
tin (200 μg/kg) and levamisole (2.5 mg/kg) was neither
macroﬁlaricidal nor more effective against the microﬁlariae
and the adult worms than ivermectin alone, although
levamisole increased ivermectin plasma bioavailability in
these patients (29).
The efﬁcacy of drugs available for the treatment of
infection with Trichuris trichiura is low in humans. Neverthe-
less, single-dose treatment with albendazole (400 mg)-
ivermectin (200 μg/kg) appears to be highly effective against
trichuriasis, being higher than when administering albenda-
zole alone or with diethylcarbamazine (6 mg/kg) (30).
Thus, ivermectin interactions with another concurrently
administered drugs can occur. This issue becames important,
as combination chemotherapy is being used with increasing
frequency as resistance to antiparasitic agents is becoming
more widespread.
Regarding bleeding disorders, haematomatous swellings
were reported in 2 out of 28 onchocerciasis patients treated
with ivermectin (150 μg/kg), and prothrombin times were
signiﬁcantly above baseline by one week to one month after
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K( 31). Nevertheless, in other 20 subjects, no changes were
observed inprothrombinnorinthromboplastintimes compared
with baseline results, during 13 days after the ingestion of 220–
420 μg/kg ofivermectin(32); bleeding disorders were not found
in 15,000 patients treated with ivermectin (150 μg/kg) (33).
Moreover, prolonged prothrombin ratios were observed in 148
subjects given ivermectin orally. Although no patients suffered
bleeding complications, factor II and VII levels were reduced
in most of them, suggesting interference with vitamin K
metabolism. Ivermectin has a minimal effect on coagulation
and concern about mass treatment for this reason appears to
be unjustiﬁed (34). Finally, a man that had been on long-term
oral anticoagulant therapy with acenocoumarol showed a
persistent, excessive hypocoagulability while using insecticides
(ivermectin and metidation) without protection to treat trees.
So, it is to be taken into account that these types of interactions
can exist and could cause hemorrhagic complications (35).
Information about the inﬂuence of foods in the pharma-
cokinetics of ivermectin is scarce. The knowledge of the
inﬂuence of alcohol in ivermectin kinetic behaviour is scarce;
co-ingestion of alcoholic drinks however is not recommended,
because of ivermectin association with GABA receptors and
the effect of alcohol in the central nervous system. In healthy
volunteers administered ivermectin orally (150 μg/kg), plasma
levels were signiﬁcantly higher when coadministered with
750 ml of beer than with 750 ml of water; the plasma
concentrations were signiﬁcantly higher in patients who drank
beer (66.3, 109, and 97.2 ng/ml at 1, 3 and 4 h, respectively)
vs. those who drank water (44.0, 67.5, and 58.7 ng/ml,
respectively, P<0.01 at each time point) (36).
Finally, ivermectin (150 μg/kg) was administered to 16
individuals with water or orange juice (750 ml). Orange juice
decreased AUC (15.7 ng·d·ml
−1) and Cmax (20.7 ng·ml
−1)
(water: 33.8 ng·ml
−1; 24.3 ng·d·ml
−1), possibly because fruit
juices and constituents are potent inhibitors of certain drug
transporters (14).
CONCLUSION
Although the efﬁcacy of ivermectin has been established
in humans against several parasite diseases, the pharmacoki-
netic properties of this compound are less well known in
humans compared to animals. Potential drug-drug interac-
tions and drug-food interactions exist for ivermectin, which
should be considered during therapeutic use of this drug.
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